Citigroup Inc. Has $3.48 Million Stake in Henry Schein, Inc. $HSIC

Citigroup Inc. reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 43.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,438 shares of the company’s stock after selling 40,554 shares during the period. Citigroup Inc.’s holdings in Henry Schein were worth $3,480,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in shares of Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after acquiring an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares during the period. Acadian Asset Management LLC acquired a new stake in Henry Schein during the first quarter worth about $676,000. Envestnet Asset Management Inc. increased its holdings in Henry Schein by 103.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 91,299 shares of the company’s stock valued at $6,669,000 after buying an additional 46,357 shares during the period. Finally, Atria Investments Inc acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $458,000. Institutional investors own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays assumed coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. JPMorgan Chase & Co. boosted their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded Henry Schein from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Finally, Mizuho lifted their target price on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $85.58.

Insiders Place Their Bets

In other Henry Schein news, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the completion of the transaction, the chief executive officer directly owned 383,803 shares in the company, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 92,943 shares of company stock worth $7,544,505. Insiders own 1.08% of the company’s stock.

Henry Schein Trading Down 0.5%

NASDAQ HSIC opened at $80.17 on Friday. The company has a market cap of $9.20 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 2.38 and a beta of 0.88. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $89.29. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The business’s fifty day moving average is $78.17 and its 200 day moving average is $72.50.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the company earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.